<DOC>
	<DOCNO>NCT00684918</DOCNO>
	<brief_summary>This protocol evaluate efficacy obatoclax old patient previously untreated AML .</brief_summary>
	<brief_title>Study Obatoclax Previously Untreated Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>The Pilot Safety portion study evaluate safety obatoclax administer 3 hour infusion 3 day row . The Pilot Schedule portion study randomize 16 patient one two cohort : 1 ) patient receive obatoclax administer 3 hour infusion 3 day row 2 ) patient receive obatoclax administer 24 hour infusion 3 day row . The schedule best overall efficacy safety Pilot Schedule portion study utilize Phase II portion study .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Histologically cytologically confirm AML No prior chemotherapy AML ( exception patient enrol Pilot Safety evaluation may 1 prior therapy ) Age ≥70 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 Patients must normal organ function define : 1 . Total bilirubin &lt; = 2 mg/dL unless result hemolysis , 2 . Aspartate transaminase ( AST [ SGOT ] ) /alanine transaminase ( ALT [ SGPT ] ) &lt; = 2.5 x institutional ULN 3 . Creatinine within normal institutional limit , OR creatinine clearance &gt; = 50 mL/min/1.73 meter square patient creatinine level institutional ULN Patients receive receiving investigational commercial agent therapy administer intent treat malignancy ( exception patient enrol pilot safety evaluation may 1 prior therapy ) patient history allergic reaction attribute component formulate product ( PEG300 polysorbate 20 ) patient history seizure disorder central nervous system leukemia patient uncontrolled , intercurrent illness include , limited , symptomatic neurological illness ; active , uncontrolled , systemic infection consider opportunistic , lifethreatening , clinically significant time treatment ; symptomatic congestive heart failure ; unstable angina pectoris ; cardiac arrhythmia ; significant pulmonary disease hypoxia ; psychiatric illness/social situation would limit compliance study requirement Human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>AML , obatoclax</keyword>
</DOC>